Edit
ImmuneOncia Therapeutics, Inc.
http://www.immuneoncia.com/immun/Last activity: 20.06.2023
Active
Immunotherapy, Cancer, 면역항암치료, Immuno-oncology, PD-L1
Location: South Korea, Gyeonggi, Seongnam-si
Investors 3
| Date | Name | Website |
| 09.05.2022 | E&Inve... | eninvestme... |
| 04.03.2022 | Dae Gyeong... | dgvc.co.kr |
| 20.06.2023 | Premier Pa... | premierpar... |
Mentions in press and media 1
| Date | Title | Description |
| 28.12.2021 | WuXi Biologics Cayman : and ImmuneOncia Sign MOU for Development and Manufacturing of Anti-PD-L1/CD47 Bispecific Antibody | WuXi Biologics and ImmuneOncia Sign MOU for Development and Manufacturing of Anti-PD-L1/CD47 Bispecific Antibody SHANGHAI, China, and SEOUL, South Korea, December 28, 2021 - WuXi Biologics ("WuXi Bio") (2269.HK), a global company ... |